OBR Daily Commentary

forumImage

Tagrisso Shows Benefit In NSCLC Patients With CNS Metastases

(PharmaTimes [UK]) June 7, 2017 - AstraZeneca has presented new data showing that Tagrisso also extends progression-free survival for non-small cell lung cancer (NSCLC) patients who have central nervous system (CNS) metastases.

Read Article arrow

H. Jack West, MD (Posted: June 07, 2017)

quotes

The results from the phase 3 AURA3 trial that directly compares osimertinib to chemotherapy in EGFR mutation-positive patients with acquired resistance to an earlier EGFR inhibitorVery clearly demonstrate a significant improvement in disease control with in the CNS with osimertinib. In addition to leading to good disease control in patients with brain metastases, there was even documented activity in a small subset of patients who have leptomeningeal carcinomatosis.

This is emerging as a very significant consideration as we follow and treat these patients longitudinally, as they have a high risk of CNS involvement.Many of us would welcome the opportunity to have EGFR mutation-positive patients receive osimertinib to treat or prevent CNS disease as soon as we could feasibly have him start on it, including ideally in patients who may not have a T790M mutation. Osimertinib emerge as an appropriate first line treatment option for EGFR mutation-positive patients based on the results of the FLAURA trial comparing it to first line gefitinib or erlotinib -- we expect to learn the results from that study as early as this fall.

quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...